Huiying Xu1, Ye Xu1, Tao Ouyang1, Jinfeng Li1, Tianfeng Wang1, Zhaoqing Fan1, Tie Fan1, Benyao Lin1, Yuntao Xie2. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Beijing Cancer Hospital & Institute, Peking University Cancer Hospital, Beijing, 100142, People's Republic of China. 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Beijing Cancer Hospital & Institute, Peking University Cancer Hospital, Beijing, 100142, People's Republic of China. zlxyt2@bjmu.edu.cn.
Abstract
BACKGROUND: RECQL is a number of the RecQ DNA helicase family and plays an important role in maintaining genome stability. Although several studies have reported that RECQL mutations were correlated with the susceptibility to breast cancer, the effect on prognosis in breast cancer was not yet clarified. Here, we explored the association between RECQL expression level and survival in patients with breast cancer. METHODS: In the first cohort, the RECQL mRNA expression level was evaluated in 774 primary breast cancer patients using a quantitative real-time PCR assay. Then, in the second independent cohort, the level of RECQL protein expression was detected in 322 patients with breast cancer using immunohistochemistry assay. Survival curves of patients with RECQL expression were compared using the Kaplan-Meier method with log-rank test. RESULTS: In the first cohort of 774 breast cancer patients, the low expression level of RECQL mRNA was significantly correlated with aggressive clinicopathological characteristics, including the positive lymph node status (P = 0.026), HER2 overexpression (P < 0.001), ER negative status (P = 0.047) and high tumor grade (P = 0.041). Moreover, the low expression level of RECQL mRNA was significantly associated with poor distant recurrence-free survival (DRFS, unadjusted hazard ratio (HR): 2.77, 95% confidence interval (CI): 1.88-4.09, P < 0.001) and disease-specific survival (DSS, unadjusted HR: 3.10, 95% CI: 1.84-5.20,P < 0.001), and it remained an independent unfavorable factor for DRFS and DSS (DRFS: adjusted HR: 3.04, 95% CI: 1.89-4.87, P < 0.001; DSS: adjusted HR: 4.25, 95% CI: 2.12-8.46, P < 0.001). In the second cohort of 322 breast cancer patients, low expression of RECQL protein was also subject to poor survival in breast cancer, and it was an independent prognosis factor of poor DRFS by multivariate analysis (DRFS: adjusted HR: 2.12, 95% CI: 1.16-3.88, P = 0.015). CONCLUSIONS: Breast cancer patients with low RECQL expression had a worse survival. The expression level of RECQL may be a potential prognosis factor for breast cancer.
BACKGROUND:RECQL is a number of the RecQ DNA helicase family and plays an important role in maintaining genome stability. Although several studies have reported that RECQL mutations were correlated with the susceptibility to breast cancer, the effect on prognosis in breast cancer was not yet clarified. Here, we explored the association between RECQL expression level and survival in patients with breast cancer. METHODS: In the first cohort, the RECQL mRNA expression level was evaluated in 774 primary breast cancerpatients using a quantitative real-time PCR assay. Then, in the second independent cohort, the level of RECQL protein expression was detected in 322 patients with breast cancer using immunohistochemistry assay. Survival curves of patients with RECQL expression were compared using the Kaplan-Meier method with log-rank test. RESULTS: In the first cohort of 774 breast cancerpatients, the low expression level of RECQL mRNA was significantly correlated with aggressive clinicopathological characteristics, including the positive lymph node status (P = 0.026), HER2 overexpression (P < 0.001), ER negative status (P = 0.047) and high tumor grade (P = 0.041). Moreover, the low expression level of RECQL mRNA was significantly associated with poor distant recurrence-free survival (DRFS, unadjusted hazard ratio (HR): 2.77, 95% confidence interval (CI): 1.88-4.09, P < 0.001) and disease-specific survival (DSS, unadjusted HR: 3.10, 95% CI: 1.84-5.20,P < 0.001), and it remained an independent unfavorable factor for DRFS and DSS (DRFS: adjusted HR: 3.04, 95% CI: 1.89-4.87, P < 0.001; DSS: adjusted HR: 4.25, 95% CI: 2.12-8.46, P < 0.001). In the second cohort of 322 breast cancerpatients, low expression of RECQL protein was also subject to poor survival in breast cancer, and it was an independent prognosis factor of poor DRFS by multivariate analysis (DRFS: adjusted HR: 2.12, 95% CI: 1.16-3.88, P = 0.015). CONCLUSIONS:Breast cancerpatients with low RECQL expression had a worse survival. The expression level of RECQL may be a potential prognosis factor for breast cancer.
Entities:
Keywords:
Breast cancer; Expression; RECQL; Survival
Authors: Cezary Cybulski; Jian Carrot-Zhang; Wojciech Kluźniak; Barbara Rivera; Aniruddh Kashyap; Dominika Wokołorczyk; Sylvie Giroux; Javad Nadaf; Nancy Hamel; Shiyu Zhang; Tomasz Huzarski; Jacek Gronwald; Tomasz Byrski; Marek Szwiec; Anna Jakubowska; Helena Rudnicka; Marcin Lener; Bartłomiej Masojć; Patrica N Tonin; Francois Rousseau; Bohdan Górski; Tadeusz Dębniak; Jacek Majewski; Jan Lubiński; William D Foulkes; Steven A Narod; Mohammad R Akbari Journal: Nat Genet Date: 2015-04-27 Impact factor: 38.330
Authors: Donghui Li; Jennifer Moughan; Christopher Crane; John P Hoffman; William F Regine; Ross A Abrams; Howard Safran; Chang Liu; Ping Chang; Gary M Freedman; Kathryn A Winter; Chandan Guha; James L Abbruzzese Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-05 Impact factor: 7.038
Authors: Sudha Sharma; Deborah J Stumpo; Adayabalam S Balajee; Cheryl B Bock; Peter M Lansdorp; Robert M Brosh; Perry J Blackshear Journal: Mol Cell Biol Date: 2006-12-11 Impact factor: 4.272
Authors: Ava Kwong; Vivian Y Shin; Isabella W Y Cheuk; Jiawei Chen; Chun H Au; Dona N Ho; Tsun L Chan; Edmond S K Ma; Mohammad R Akbari; Steven A Narod Journal: Breast Cancer Res Treat Date: 2016-04-28 Impact factor: 4.872
Authors: Venkateswarlu Popuri; Joseph Hsu; Prabhat Khadka; Kent Horvath; Yie Liu; Deborah L Croteau; Vilhelm A Bohr Journal: Nucleic Acids Res Date: 2014-03-12 Impact factor: 16.971
Authors: Ardalan Mahmoodi; Ahmed Shoqafi; Ping Sun; Vasily Giannakeas; Cezary Cybulski; Sharon Nofech-Mozes; Jean-Yves Masson; Sudha Sharma; Amir Abbas Samani; Srinivasan Madhusudan; Steven A Narod; Mohammad R Akbari Journal: Front Oncol Date: 2022-05-31 Impact factor: 5.738